Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 2, 2008, Pages 783-793

  Zeng, Fanxing ^a   Jarkas, Nachwa ^a   Stehouwer, Jeffrey S ^a   Voll, Ronald J ^a   Owens, Michael J ^a   Kilts, Clinton D ^a   Nemeroff, Charles B ^a   Goodman, Mark M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

(S, S)Reboxetine analogs; Carbon 11; Fluorine 18; Norepinephrine transporter; Positron Emission Tomography

Indexed keywords

2 [ALPHA(2 METHOXYPHENYLTHIO)PHENYLMETHYL]MORPHOLINE C 11; 2 [ALPHA[2 (2 FLUOROETHOXY)PHENYLTHIO]BENZYL]MORPHOLINE F 18; 2 [ALPHA[2 (3 FLUOROPROPOXY)PHENYLTHIO]BENZYL]MORPHOLINE F 18; 2 [ALPHA[2 (CARBOMETHOXY)PHENOXY]BENZYL]MORPHOLINE C 11; 2 [ALPHA[2 (CARBOMETHOXY)PHENYLTHIO]BENZYL]MORPHOLINE C 11; 2 [ALPHA[2 (METHYLTHIO)PHENOXY]BENZYL]MORPHOLINE C 11; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBON 11; CITALOPRAM; DOPAMINE TRANSPORTER; FLUORINE 18; FLUORINE DERIVATIVE; FLUOROETHYLBROSYLATE F 18; FLUOROPROPYLBROSYLATE F 18; IODINE 125; NISOXETINE; NORADRENALIN TRANSPORTER; RADIOLIGAND; REBOXETINE; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG PURITY; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; ENANTIOMER; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; METHYLATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLUORINE RADIOISOTOPES; HUMANS; MOLECULAR STRUCTURE; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PRIMATES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

PRIMATES;

EID: 38549120307     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.10.025     Document Type: Article

References (33)

1. Blakely R.D., DeFelice L.J., and Hartzell H.C. J. Exp. Biol. 196 (1994) 263
2. Pacholcyzk T., Blakely R.D., and Amara S.G. Nature 350 (1991) 350
3. Galli A., DeFelice L.J., Duke B.J., Moore K.R., and Blakely R.D. J. Exp. Biol. 198 (1995) 2197
4. Ordway G.A., and Klimek V. CNS Spectrums 6 (2001) 697
5. Ressler K.J., and Nemeroff C.B. Biol. Psychiatry 46 (1999) 1219
6. Lee C.M., and Snyder S.H. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 5250
7. Biegon A., and Rainbow T. J. Neurosci. 3 (1983) 1069
8. Van Dort M.E., Kim J.H., Tluczek L., and Wieland D.M. Nucl. Med. Biol. 24 (1997) 707
9. Tejani-Butt S.M. J. Phar. Exp. Ther. 260 (1992) 427
10. Haka M.S., and Kilbourn M.R. Nucl. Med. Biol. 16 (1989) 771
11. Ding Y.-S., Lin K.-S., Logan J., Benveniste H., and Carter P. J. Neurochem. 94 (2005) 337
12. Kung M.-P., Choi S.-R., Hou C., Zhuang Z.-P., Foulon C., and Kung H.F. Nucl. Med. Biol. 31 (2004) 533
13. McConathy J., Owen M.J., Kilts C.D., Malveaux E.J., Camp V.M., Votaw J.R., Nemeroff C.B., and Goodman M.M. Nucl. Med. Biol. 31 (2004) 705
14. Ding Y.-S., Lin K.S., Gaza V., Carter P., Alexoff D., Logan J., et al. Synapse 50 (2003) 345
15. Wilson A.A., Johnson D.P., Mozley D., Hussey D., Ginovart N., Nobrega J., Garcia A., Meyer J., and Houls S. Nucl. Med. Biol. 30 (2003) 85
16. Schou M., Halldin C., Sovago J., Pike V.W., Gulyas B., Mozley P.D., Johnson D.P., Hall H., Innis R.B., and Farde L. Nucl. Med. Biol. 30 (2003) 707
17. Schou M., Halldin C., Sovago J., Pike V.W., Hall H., Gulyas B., Mozley P.D., Dobson D., Shchukin E., Innis R.B., and Farde L. Synapse 53 (2004) 57
18. Seneca N., Gulyas B., Varrone A., Schou M., Airaksinen A., Tauscher J., Vandenhende F., Kielbasa W., Farde L., Innis R.B., and Halldin C. Psychopharmacology 188 (2006) 119
19. Kanegawa N., Kiyono Y., Kimura H., Sugita T., Kajiyama S., Kawashima H., Ueda M., Kuge Y., and Saji H. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 639
20. Tamagnan G.D., Brenner E., Alagille D., Staley J.K., Haile C., Koren A., Early M., Baldwin R.M., Tarazi F.I., Baldessarini R.J., Jarkas N., Goodman M.M., and Seibyl J.P. Bioorg. Med. Chem. Lett. 17 (2007) 533
21. Lin K.-S., Ding Y.-S., Kim S.-W., and Kil K.-E. Nucl. Med. Biol. 32 (2005) 415
22. In a paper, see Ref. 25, J. Boot et al., reported that the racemic mixture of compound 3 containing (S, S) and (R,R) enantiomers was prepared and resolved using chiral HPLC. One enantiomer was found to be potent and selective toward NET, whereas the opposite enantiomer was potent for both the NET and SERT. However, the assignment of absolute stereochemistry of resolved enantiomers was not reported in this paper.
23. Brenner E., Baldwin R.M., and Tamagnan G. Org. Lett 7 (2005) 937
24. Mitsunobu O. Synthesis (1981) 1
25. Boot J., Cases M., Clark B.P., Findlay J., Gallagher P.T., Hayhurst L., Man T., Montalbetti C., Rathmell R.E., Rudyk H., Walter M.W., Whatton M., and Wood V. Bioorg. Med. Chem. Lett. 15 (2005) 699
26. Wilson A.A., DaSilva J.N., and Houle S. Appl. Radiat. Isot. 46 (1995) 765
27. Millington J.E., and Pattison F.L.M. Can. J. Chem. 34 (1956) 1532
28. Zessin J., Gucker P., Ametamey S.M., Steinbach J., Brust P., Vollenweider F.X., Johannsen B., and Schubiger P.A. J. Label. Compd. Radiopharm. 42 (1999) 1301
29. Schou M., Pike V.W., Varrone A., Gulyás B., Farde L., and Halldin C. J. Label. Compd. Radiopharm. 49 (2006) 1007
30. Wilson A.A., and Houle S. J. Label. Compd. Radiopharm. 42 (1999) 1277
31. Dischino D.D., Welch M.J., Kilbourn M.R., and Raichle M.E. J. Nucl. Med. 24 (1983) 1030
32. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305
33. Plisson C., McConathy J., Martarello L., Malveaux E.J., Camp V.M., Williams L., Votaw J.R., and Goodman M.M. J. Med. Chem. 47 (2004) 1122